Zydus Lifesciences has shared an important regulatory update that signals steady progress at one of its key manufacturing sites. The company has received the Establishment Inspection Report (EIR) from the USFDA for the follow-up GMP inspection carried out at its injectable facility in Jarod, Vadodara. The inspection took place between August 25 and September 5, 2025, and the facility has now been classified under the Voluntary Action Indicated (VAI) category.
This classification generally reflects that the regulator has identified certain observations, but none that require immediate enforcement action. It also indicates that the facility is moving in the right direction as it works through the compliance expectations set by the USFDA. The follow-up inspection was part of the process triggered by the Warning Letter the company received on August 29, 2024.
With the issuance of the EIR, Zydus has taken another step toward strengthening its regulatory standing for the Vadodara injectable unit.